We are live on ! Find out more
NRSN icon

NeuroSense Therapeutics
NRSN

12 hedge funds and large institutions have $286K invested in NeuroSense Therapeutics in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.08% more ownership

Funds ownership: 1.14% → 1.22% (+0.08%)

0% less capital invested

Capital invested by funds: $287K → $286K (-$905)

8% less funds holding

Funds holding: 13 → 12 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$46.4K
2
IAA
Independent Advisor Alliance
North Carolina
+$39K
3
XT
XTX Topco
Cayman Islands
+$8.95K
4
HF
HRT Financial
New York
+$8.2K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$33.6K
2
MIH
Meitav Investment House
Israel
-$30.2K
3
Jane Street
Jane Street
New York
-$21.6K
4
Creative Planning
Creative Planning
Kansas
-$390

NRSN Hedge Fund Activity: Q2 2026 in Review

12 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q2 2026, worth a combined $286K — down 0.32% from $287K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of NRSN and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $46.4K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $33.6K sold.

  • 12 institutional investors held NeuroSense Therapeutics (NRSN) as of Q2 2026, down from 13 in Q1 2026.
  • Funds reported $286K of NeuroSense Therapeutics stock for Q2 2026, down 0.32% quarter-over-quarter.
  • 2 funds opened new NeuroSense Therapeutics positions in Q2 2026 and 3 closed out, a net change of -1 holder.
  • The largest NeuroSense Therapeutics buyer in Q2 2026 was UBS Group, an estimated $46.4K added.
  • The largest NeuroSense Therapeutics seller in Q2 2026 was Two Sigma Investments, an estimated $33.6K sold.

Based on aggregated 13F filings for Q2 2026.